AstraZeneca’s Farxiga has become the latest type 2 diabetes drug to show it can reduce cardiovascular risk in a clinical trial. Boehringer Ingelheim and Eli Lilly’s Jardiance (empagliflozin ...

For Medicare beneficiaries, its list price went down 56% to $231, from a list price of $521 The blockbuster drug Farxiga was approved by the FDA in 2014 to treat type 2 diabetes and has since ...

AstraZeneca continues to make the case for its Farxiga diabetes drug, highlighting a cardiology analysis that it hopes will convince more doctors to prescribe it in a highly competitive market.

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

The Trump administration made a decidedly pro-industry statement on the Inflation Reduction Act (IRA). In an executive order issued Tuesday, President Donald Trump outlined changes to the Biden ...

New research suggests that GLP-1 drugs like Ozempic and Wegovy, commonly used for diabetes and weight loss, may also reduce the risk of Alzheimer's disease and dementia.